Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

American Society of Hematology 2016 annual meeting

American Society of Hematology 2016 annual meeting For heterogeneous myelodysplastic syndromes (MDS), patient management is still a challenge. Despite the progress achieved in recent years, there is need for improvement at least for specific situations such as failure of hypomethylating agents or in patients with thrombocytopenia or with anemia failing erythropoiesis stimulating agents. This review covers studies for MDS presented at the American Society of Hematology (ASH) 2016 annual meeting. New treatment approaches, for which results from phase 1/2 studies were reported, will now move into phase 3 and hopefully into clinical practice in the future. Choosing the right agent and individualizing treatment will be the next challenges. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

American Society of Hematology 2016 annual meeting

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/american-society-of-hematology-2016-annual-meeting-j7rU0z0yVk
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0330-8
Publisher site
See Article on Publisher Site

Abstract

For heterogeneous myelodysplastic syndromes (MDS), patient management is still a challenge. Despite the progress achieved in recent years, there is need for improvement at least for specific situations such as failure of hypomethylating agents or in patients with thrombocytopenia or with anemia failing erythropoiesis stimulating agents. This review covers studies for MDS presented at the American Society of Hematology (ASH) 2016 annual meeting. New treatment approaches, for which results from phase 1/2 studies were reported, will now move into phase 3 and hopefully into clinical practice in the future. Choosing the right agent and individualizing treatment will be the next challenges.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: May 16, 2017

References

  • Myelodysplastic syndromes: contemporary review and how we treat
    Gangat, N; Patnaik, MM; Tefferi, A
  • The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
    Arber, DA; Orazi, A; Hasserjian, R
  • Predictive value of mutation analysis in the diagnostic approach to patients with unexplained cytopenia
    Malcovati, L; Gallì, A; Travaglino, E
  • Incorporation of molecular data into the current prognostic models in treated patients with myelodysplastic syndromes: Which model is the best?
    Al-Issa, K; Zarzour, A; Radivoyevitch, T
  • Toll-like receptor alterations in myelodysplastic syndrome
    Wei, Y; Dimicoli, S; Bueso-Ramos, C
  • Toll like receptor 2/6 but not 1/2 signaling promotes leukemogenesis in a mouse model of myelodysplastic syndrome
    Bhatt, ST; Monlish, D; Duncavage, EJ
  • A clinical study of OPN-305, a toll-like receptor 2 (TLR-2) antibody, in patients with lower risk myelodysplastic syndromes (MDS) that have received prior Hypomethylating agent (HMA) therapy
    Garcia-Manero, G; Montalban-Bravo, G; Yang, H
  • New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or MDS: results of the randomized, phase II E.C.L.I.P.S.E. study
    Taher, AT; Origa, R; Perrotta, S
  • Improved patient-reported outcomes with a film-coated versus dispersible tablet formulation of deferasirox: results from the randomized, phase II E.C.L.I.P.S.E. study
    Taher, AT; Origa, R; Perrotta, S
  • Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload: the Rythmex study
    Rose, C; Fitoussi, O; Gyan, E
  • A phase 3 randomized placebo (PBO)-controlled double-blind trial of darbepoetin alfa in the treatment of anemia in patients with low or intermediate-1 (int-1) risk myelodysplastic syndromes (MDS)
    Platzbecker, U; Symeonidis, A; Oliva, EN
  • A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q
    Fenaux, P; Giagounidis, A; Selleslag, D
  • Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) Myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents
    Santini, V; Almeida, A; Giagounidis, A
  • Lenalidomide stabilizes the erythropoietin receptor by inhibiting the E3 ubiquitin ligase RNF41
    Basiorka, AA; McGraw, KL; Ceuninck, L
  • Combined treatment with lenalidomide (LEN) and epoetin alfa (EA) is superior to lenalidomide alone in patients with erythropoietin (Epo)-refractory, lower risk (LR) non-deletion 5q [del(5q)] Myelodysplastic syndrome (MDS): results of the E2905 intergroup study-an ECOG-ACRIN cancer research group study, grant CA180820, and the National Cancer Institute of the National Institutes of Health
    List, AF; Sun, Z; Verma, A
  • Lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor shows efficacy in patients with low and intermediate-1 risk Myelodysplastic syndrome with or without del 5q, refractory or unlikely to respond to erythropoietin. Results of a HOVON89 phase II randomized multicenter study. (EudraCT 2008-002195-10)
    Loosdrecht, AA; Chitu, DA; Cremers, EMP
  • Luspatercept increases hemoglobin and reduces transfusion burden in patients with low-intermediate risk myelodysplastic syndromes (MDS): long-term results from phase 2 PACE-MDS study
    Platzbecker, U; Germing, U; Götze, U
  • Safety and efficacy of the CD95-ligand inhibitor APG101 in transfusion-dependent patients with low risk MDS: results from a phase I study
    Boch, T; Luft, T; Mossner, M
  • A randomized phase II study of low-dose decitabine versus azacitidine in patients with low- or intermediate-1-risk myelodysplastic syndromes: a report on behalf of the MDS clinical research consortium
    Jabbour, EJ; Short, NJ; Huang, X
  • Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
    Prébet, T; Gore, SD; Esterni, B
  • Enasidenib (AG-221), a potent oral inhibitor of mutant Isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS)
    Stein, EM; Fathi, AT; DiNardo, CD
  • Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of mutant IDH1
    DiNardo, CD; Botton, S; Stein, EM
  • The blockade of immune checkpoints in cancer immunotherapy
    Pardoll, DM
  • Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
    Yang, H; Bueso-Ramos, C; DiNardo, C
  • A phase II study evaluating the combination of nivolumab (Nivo) or Ipilimumab (Ipi) with azacitidine in pts with previously treated or untreated myelodysplastic syndromes (MDS)
    Garcia-Manero, G; Daver, NG; Montalban-Bravo, G
  • Pembrolizumab, a PD-1 inhibitor, in patients with myelodysplastic syndrome (MDS) after failure of hypomethylating agent treatment
    Garcia-Manero, G; Tallman, MS; Martinelli, G